Inhibitory/suppressive oligodeoxynucleotide nanocapsules as simple oral delivery devices for preventing atopic dermatitis in mice

Molecular Therapy

Volumn 23, Issue 2, 2015, Pages 297-309

  Wang, Yeqin ^a   Yamamoto, Yoshinari ^a   Shigemori, Suguru ^a,b   Watanabe, Takafumi ^a   Oshiro, Kazushi ^a   Wang, Xinyu ^a   Wang, Pengfei ^a   Sato, Takashi ^c   Yonekura, Shinichi ^a   Tanaka, Sachi ^a   Kitazawa, Haruki ^d   Shimosato, Takeshi ^a  

^a SHINSHU UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CALCIUM CHLORIDE; CD11B ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN E; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; NANOCAPSULE; STAT6 PROTEIN; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CONFOCAL LASER MICROSCOPY; CONTINUOUS INFUSION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; ENCAPSULATION; FLOW CYTOMETRY; HELPER CELL; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LABORATORY DIAGNOSIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PERITONEUM MACROPHAGE; PEYER PATCH; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; SKIN DEFECT; TH2 CELL; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DERMATITIS, ATOPIC; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MACROPHAGE ACTIVATION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; ULTRASTRUCTURE;

MUS;

ADMINISTRATION, ORAL; ANIMALS; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; INTERLEUKIN-33; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; NANOCAPSULES; OLIGODEOXYRIBONUCLEOTIDES; PEYER'S PATCHES; SIGNAL TRANSDUCTION; TH2 CELLS;

EID: 84961290704     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.239     Document Type: Article

References (50)

1. Krieg AM, Yi, AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R., et al. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549
2. Costa LB, Noronha FJ, Roche JK, Sevilleja JE, Warren CA, Oria R., et al. (2012). Novel in vitro and in vivo models and potential new therapeutics to break the vicious cycle of Cryptosporidium infection and malnutrition. J Infect Dis 205: 1464-1471
3. Karbach J, Neumann A, Wahle C, Brand K, Gnjatic S and Jager E. (2012). Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies. Cancer Res 72: 4304-4310
4. Klinman DM. (2004). Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4: 249-258
5. Pico de Coana Y, Carnes J, Gallego MT, Alonso C and Parody N. (2012). Modulation of the humoral response to Dermatophagoides pteronyssinus allergens in BALB/c mice by extract modification and adjuvant use. Int Arch Allergy Immunol 157: 331-338
6. Sester DP, Naik S, Beasley SJ, Hume DA and Stacey KJ. (2000). Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol 165: 4165-4173
7. Klaschik S, Tross D, Shirota H and Klinman DM. (2010). Short- and long-term changes in gene expression mediated by the activation of TLR9. Mol Immunol 47: 1317-1324
8. Asanuma H, Zamri NB, Sekine S, Fukuyama Y, Tokuhara D, Gilbert RS., et al. (2012). A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging. Vaccine 30: 803-812
9. Cheng WK, Wee K, Kollmann TR and Dutz JP. (2014). Topical CpG adjuvantation of a protein-based vaccine induces protective immunity to Listeria monocytogenes. Clin Vaccine Immunol 21: 329-339
10. Ito Y, Shigemori S, Sato T, Shimazu T, Hatano K, Otani H., et al. (2013). Class I/II hybrid inhibitory oligodeoxynucleotide exerts Th1 and Th2 double immunosuppression. FEBS Open Bio 3: 41-45
11. Shimosato T, Fujimoto M, Tohno M, Sato T, Tateo M, Otani H., et al. (2010). CpG oligodeoxynucleotides induce strong up-regulation of interleukin 33 via Toll-like receptor 9. Biochem Biophys Res Commun 394: 81-86
12. Gursel M, Verthelyi D, Gursel I, Ishii KJ and Klinman DM. (2002). Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 71: 813-820
13. Chowdhury EH. (2011). Fluoride enhances transfection activity of carbonate apatite by increasing cytoplasmic stability of plasmid DNA. Biochem Biophys Res Commun 409: 745-747
14. Kutsuzawa K, Akaike T and Chowdhury EH. (2008). The influence of the cell-adhesive proteins E-cadherin and fibronectin embedded in carbonate-apatite DNA carrier on transgene delivery and expression in a mouse embryonic stem cell line. Biomaterials 29: 370-376
15. Luo D and Saltzman WM. (2000). Synthetic DNA delivery systems. Nat Biotechnol 18: 33-37
16. Yamaguchi J, Nakamura F, Aihara M, Yamashita N, Usui H, Hida T., et al. (2008). Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice an atopic dermatitis model. J Invest Dermatol 128: 2842-2849
17. Shigemori S, Yonekura S, Sato T, Otani H and Shimosato T. (2013). Expression of the immunoreactive buckwheat major allergenic storage protein in Lactococcus lactis. Appl Microbiol Biotechnol 97: 3603-3611
18. Choudhury BK, Wild JS, Alam R, Klinman DM, Boldogh I, Dharajiya N., et al. (2002). In vivo role of p38 mitogen-activated protein kinase in mediating the antiinflammatory effects of CpG oligodeoxynucleotide in murine asthma. J Immunol 169: 5955-5961
19. Hattori K, Nishikawa M, Watcharanurak K, Ikoma A, Kabashima K, Toyota H., et al. (2010). Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. J Immunol 184: 2729-2735
20. Inoue J and Aramaki Y. (2007). Suppression of skin lesions by transdermal application of CpG-oligodeoxynucleotides in NC/Nga mice a model of human atopic dermatitis. J Immunol 178: 584-591
21. Lee SY, Cho JY, Miller M, McElwain K, McElwain S, Sriramarao P., et al. (2006). Immunostimulatory DNA inhibits allergen-induced peribronchial angiogenesis in mice. J Allergy Clin Immunol 117: 597-603
22. Park Y, Chang YS, Lee SW, Cho SY, Kim YK, Min KU., et al. (2001). The enhanced effect of a hexameric deoxyriboguanosine run conjugation to CpG oligodeoxynucleotides on protection against allergic asthma. J Allergy Clin Immunol 108: 570-576
23. Sugai T, Mori M, Nakazawa M, Ichino M, Naruto T, Kobayashi N., et al. (2005). A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine. Vaccine 23: 5450-5456
24. Volpi C, Fallarino F, Pallotta MT, Bianchi R, Vacca C, Belladonna ML., et al. (2013). High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat Commun 4: 1852
25. Youn CJ, Miller M, Baek KJ, Han JW, Nayar J, Lee SY., et al. (2004). Immunostimulatory DNA reverses established allergen-induced airway remodeling. J Immunol 173: 7556-7564
26. Takakura M, Takeshita F, Aihara M, Xin KQ, Ichino M, Okuda K., et al. (2005). Hyperproduction of IFN-gamma by CpG oligodeoxynucleotide-induced exacerbation of atopic dermatitis-like skin lesion in some NC/Nga mice. J Invest Dermatol 125: 1156-1162
27. Kakkar R and Lee RT. (2008). The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7: 827-840
28. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK., et al. (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490
29. Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S and Zaheer A. (2014). Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis 40: 297-308
30. Haenuki Y, Matsushita K, Futatsugi-Yumikura S, Ishii KJ, Kawagoe T, Imoto Y., et al. (2012). A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol 130: 184-94.e11
31. Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T., et al. (2013). Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA 110: 13921-13926
32. Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F and Klinman DM. (2003). Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol 171: 1393-1400
33. Klinman DM, Gursel I, Klaschik S, Dong L, Currie D and Shirota H. (2005). Therapeutic potential of oligonucleotides expressing immunosuppressive TTAGGG motifs. Ann N Y Acad Sci 1058: 87-95
34. Shirota H, Gursel I, Gursel M and Klinman DM. (2005). Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol 174: 4579-4583
35. Shirota H, Gursel M and Klinman DM. (2004). Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma- and IL-12-mediated signaling. J Immunol 173: 5002-5007
36. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA., et al. (2013). Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342: 967-970
37. Lee YK and Mazmanian SK. (2010). Has the microbiota played a critical role in the evolution of the adaptive immune system?. Science 330: 1768-1773
38. Pickard JM, Maurice CF, Kinnebrew MA, Abt MC, Schenten D, Golovkina TV., et al. (2014). Rapid fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness. Nature 514: 638-641
39. Ballarin-Gonzalez B, Dagnaes-Hansen F, Fenton RA, Gao S, Hein S, Dong M., et al. (2013). Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles. Mol Ther Nucleic Acids 2: e76
40. Lautenschlager C, Schmidt C, Lehr CM, Fischer D and Stallmach A. (2013). PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur J Pharm Biopharm 85(3 Pt A): 578-586
41. Mamaeva V, Rosenholm JM, Bate-Eya LT, Bergman L, Peuhu E, Duchanoy A., et al. (2011). Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol Ther 19: 1538-1546
42. Mitragotri S, Burke PA and Langer R. (2014). Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 13: 655-672
43. Wang B, Zhuang X, Deng ZB, Jiang H, Mu, J, Wang Q., et al. (2014). Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol Ther 22: 522-534
44. Kunisawa J, Kurashima Y and Kiyono H. (2012). Gut-associated lymphoid tissues for the development of oral vaccines. Adv Drug Deliv Rev 64: 523-530
45. Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters RC., et al. (2012). Large intestine-targeted nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med 18: 1291-1296
46. Fukuda K, Kutsuzawa K, Maruyama K, Akiyama Y and Chowdhury EH. (2012). Synergistic effect of PKC activation and actin filament disruption on carbonate apatite-facilitated lymphocyte transfection. Biochem Biophys Res Commun 419: 482-484
47. Maeyama J, Takatsuka H, Suzuki F, Kubota A, Horiguchi S, Komiya T., et al. (2014). A palindromic CpG-containing phosphodiester oligodeoxynucleotide as a mucosal adjuvant stimulates plasmacytoid dendritic cell-mediated T(H)1 immunity. PLoS ONE 9: e88846
48. Ito S, Ishii KJ, Ihata A and Klinman DM. (2005). Contribution of nitric oxide to CpGmediated protection against Listeria monocytogenes. Infect Immun 73: 3803-3805
49. Cengiz S, Sarac S and Ozcan M. (2014). Effects of simulated gastric juice on color stability surface roughness and microhardness of laboratory-processed composites. Dent Mater J 33: 343-348
50. Hamasaka A, Abe R, Koyama Y, Yoshioka N, Fujita Y, Hoshina D., et al. (2009). DNA vaccination against macrophage migration inhibitory factor improves atopic dermatitis in murine models. J Allergy Clin Immunol 124: 90-99